Johnson & Johnson (NYSE:JNJ) is Asset Advisors Investment Management LLC’s 6th Largest Position

Asset Advisors Investment Management LLC lessened its holdings in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 0.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 140,571 shares of the company’s stock after selling 925 shares during the period. Johnson & Johnson makes up approximately 3.3% of Asset Advisors Investment Management LLC’s portfolio, making the stock its 6th biggest holding. Asset Advisors Investment Management LLC’s holdings in Johnson & Johnson were worth $22,964,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Atria Investments LLC grew its holdings in Johnson & Johnson by 2.2% during the third quarter. Atria Investments LLC now owns 190,052 shares of the company’s stock worth $31,047,000 after acquiring an additional 4,093 shares during the period. Smith Salley & Associates grew its holdings in Johnson & Johnson by 1.7% in the third quarter. Smith Salley & Associates now owns 50,354 shares of the company’s stock valued at $8,226,000 after purchasing an additional 839 shares during the last quarter. Mattern Wealth Management LLC grew its holdings in Johnson & Johnson by 0.7% in the third quarter. Mattern Wealth Management LLC now owns 27,512 shares of the company’s stock valued at $4,494,000 after purchasing an additional 198 shares during the last quarter. Prestige Wealth Management Group LLC grew its holdings in Johnson & Johnson by 3.8% in the third quarter. Prestige Wealth Management Group LLC now owns 32,134 shares of the company’s stock valued at $5,250,000 after purchasing an additional 1,171 shares during the last quarter. Finally, M&G Investment Management Ltd. grew its holdings in Johnson & Johnson by 2.1% in the third quarter. M&G Investment Management Ltd. now owns 521,248 shares of the company’s stock valued at $84,963,000 after purchasing an additional 10,664 shares during the last quarter. Institutional investors and hedge funds own 67.94% of the company’s stock.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $168.74 on Monday. The business’s 50-day moving average price is $176.14 and its 200 day moving average price is $171.20. Johnson & Johnson has a twelve month low of $155.72 and a twelve month high of $186.69. The company has a market capitalization of $441.17 billion, a PE ratio of 23.50, a price-to-earnings-growth ratio of 3.19 and a beta of 0.56. The company has a current ratio of 1.43, a quick ratio of 1.18 and a debt-to-equity ratio of 0.37.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st will be issued a $1.13 dividend. The ex-dividend date is Friday, February 17th. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.68%. Johnson & Johnson’s dividend payout ratio (DPR) is 62.95%.

Insider Transactions at Johnson & Johnson

In other news, VP Thibaut Mongon sold 35,246 shares of the firm’s stock in a transaction dated Friday, November 4th. The stock was sold at an average price of $171.18, for a total value of $6,033,410.28. Following the transaction, the vice president now directly owns 40,133 shares in the company, valued at approximately $6,869,966.94. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, VP Thibaut Mongon sold 35,246 shares of the firm’s stock in a transaction dated Friday, November 4th. The stock was sold at an average price of $171.18, for a total value of $6,033,410.28. Following the transaction, the vice president now directly owns 40,133 shares in the company, valued at approximately $6,869,966.94. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Joseph J. Wolk sold 14,781 shares of the firm’s stock in a transaction dated Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total value of $2,654,667.60. Following the completion of the transaction, the chief financial officer now owns 35,812 shares in the company, valued at $6,431,835.20. The disclosure for this sale can be found here. Insiders have sold a total of 233,611 shares of company stock worth $40,960,735 in the last three months. 0.35% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. Credit Suisse Group assumed coverage on Johnson & Johnson in a report on Thursday, November 17th. They issued a “neutral” rating and a $170.00 target price on the stock. Morgan Stanley lowered their target price on Johnson & Johnson from $178.00 to $176.00 and set an “equal weight” rating on the stock in a report on Tuesday, December 6th. SVB Leerink lowered their target price on Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating on the stock in a report on Friday. Atlantic Securities reduced their price objective on Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating on the stock in a research report on Wednesday, October 19th. Finally, Barclays assumed coverage on Johnson & Johnson in a research report on Monday, October 17th. They issued an “equal weight” rating and a $175.00 price objective on the stock. Seven equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average target price of $181.75.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

See Also

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.